36
Participants
Start Date
December 31, 2010
Primary Completion Date
April 24, 2017
Study Completion Date
April 24, 2018
Everolimus
10 mg PO daily (continuously, without scheduled treatment interruptions). The cycle length will last 28 days. Everolimus will be dispensed on Day 1 of each cycle by the study center personnel on an outpatient basis.
Everolimus
10 mg PO daily (continuously, without scheduled treatment interruptions). The cycle length will last 28 days. Everolimus will be dispensed on Day 1 of each cycle by the study center personnel on an outpatient basis.
Paclitaxel
Paclitaxel 80 mg/m2 IV as a 1 hour infusion on days 1, 8, and 15, of a 28-day cycle.
Icahn School of Medicine: Tisch Cancer Institute at Mount Sinai Medical Center, New York
Virginia Oncology Associates, Norfolk
MUSC Hollings Cancer Center, Charleston
University of Alabama Hematology Oncology Clinic at Medical West, Birmingham
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis
IU Health Central Indiana Cancer Centers, Indianapolis
Cancer Care Center of Southern Indiana, Bloomington
Metro Health Cancer Care, Wyoming
Northwestern University, Robert H. Lurie Comprehensive Cancer Center, Chicago
Nebraska Cancer Specialists, Omaha
University of Texas Medical Branch, Galveston
Collaborators (2)
Hoosier Cancer Research Network
OTHER
Novartis Pharmaceuticals
INDUSTRY
Matthew Galsky
OTHER